Oura Inc. S-1/Aamended IPO prospectus

Executive Summary

Oura sells smart rings that feed personalized health insights into paid memberships, combining hardware-led acquisition with high-margin recurring revenue. FY2025 revenue grew 123% to $908M with near-breakeven net income; 9M FY2026 revenue grew 74.1% to $1.21B, generating $60.8M net income, although spending outpaced sales growth. The unpriced IPO offers $2.00B–$2.20B of shares at an implied $12.8B–$14.1B capitalization, giving buyers 15.6% ownership; 73% of shares sold are secondary. At 14.1–15.6× FY2025 revenue, investors are paying for sustained adoption and subscription expansion, while almost all company proceeds fund taxes on vesting employee awards rather than growth.

The Offering

• Size and implied valuation: 50.0M shares at $40.00–$44.00 generate $2.00B–$2.20B gross proceeds. Using the prospectus’s 320.945M post-offering shares, implied capitalization is $12.8B–$14.1B, buyer ownership 15.6%, and FY2025 revenue multiple 14.1–15.6×; the earnings multiple exceeds 1M× because FY2025 net income was only $0.012M. Including excluded options and remaining stock-unit awards gives 356M fully diluted shares, $14.2B–$15.7B capitalization and 14.1% buyer ownership, before future plan grants.
• Distribution: 13.5M primary shares raise $540M–$594M gross for Oura; 36.5M secondary shares raise $1.46B–$1.61B for existing holders. The 7.5M-share over-allotment option is entirely secondary. Proposed listing: Nasdaq Global Select Market, OURA. The offering remains unpriced.
• Proceeds: At $42.00, estimated company net proceeds are $533M; $526M, or 98.8%, funds tax withholding on vesting restricted stock units, leaving $6.2M for general corporate purposes. No offering proceeds repay debt.
• Asset backing: Each $42.00 share is backed by $(0.69) of net tangible assets after the IPO, a $42.69 gap. Existing holders’ average consideration was $5.21 per share; the valuation therefore rests on future earnings, not tangible assets.
• Capitalization bridge: “After IPO” assumes preferred-stock and convertible-investment conversions, award settlement and the offering. Preferred conversion adds $1.50B to equity, and Eli Lilly’s $50.0M investment converts into 1.19M shares at the midpoint; award-tax obligations offset $526M. Equity moves from $(1.62)B before the IPO to $(594)M after conversions and settlement, then $(62.8)M after issuance. Cash rises only $6.16M; debt is unchanged.
• Allocations: Eli Lilly and Dragoneer indicate nonbinding purchases of up to $100M and $300M within the IPO. Up to 7.5% is reserved for management-selected directed-share participants; both arrangements reduce general-public availability.
• Sale overhang: General lock-ups last 180 days, but staged releases begin on day 35 and price-triggered releases can unlock up to ≈51.0M shares within 60 days. Restricted shares total 271M, with registration rights covering 65.1M; supply can expand well before the general lock-up ends.

Key Financial Highlights

Fiscal years end September 30. Amounts are $M unless indicated; balance-sheet figures are historical except the labeled after-IPO column.

¹ Purchases of property, equipment and intangible assets; the subtraction is computed, not company-defined FCF.

• Equity deficit: $1.50B of convertible preferred stock sits outside historical stockholders’ equity; accumulated losses and repurchases above carrying value deepen the deficit. Debt explains only part of total liabilities.
• Preferred accounting: Repurchases generated a $985M accounting allocation to preferred holders in 9M FY2026, turning $60.8M consolidated profit into a $(924)M common-stockholder result—not an operating loss.
• Margins: FY2025 warranty expense increased $84.4M; newer cohorts and lower manufacturing costs supported the subsequent gross-margin recovery. Operating margin nevertheless fell to 5.86% from 8.64% as operating expenses nearly doubled.
• Cash conversion: Non-cash charges and working capital, including $177M from accrued liabilities and $52.4M from deferred revenue, explain OCF exceeding profit. Financing outflows included $1.17B of repurchases, consuming cash despite positive operations.
• Earnings durability: FY2025’s near-zero profit reflected debt-extinguishment costs and a nearly 100% effective tax rate; Q3 FY2026 still recorded a $(9.97)M loss. IPO-linked vesting adds ≈$160M of stock-based compensation.

Business Model and Growth Drivers

• Revenue mix: Hardware contributed 80% of 9M FY2026 sales; membership contributed 20%, up from 16%, with 89% membership gross margin. Hardware is intended to recover acquisition costs, while subscriptions extend customer value.
• Adoption: Rings Sold—recognized shipments net of returns and specified replacements—reached 3.1M in 9M FY2026, up 75%; Paid Members doubled to 5.0M. Management expects ≈5.7M members at FY2026 year-end.
• Retention: ≈94% of activations convert to paid membership; weighted-average 12-month retention is ≈85%, including qualifying winbacks. Paid Members include grace-period accounts and certain concessions, so the count is broader than uninterrupted paying subscribers.
• Expansion: Ring 5 launched 6/4/2026; management targets international, retail and healthcare distribution. Retail supplied ≈49% of hardware revenue, while international hardware remained below 20%. Two customers supplied 12% and 10% of total revenue, making partner execution material.
• Differentiation: Nearly 42B hours of biometric data support personalized models; women constitute ≈72% of members. Preventive-health and women’s-health features could deepen subscription value, but investigational functionality requires validation.

Governance and Control

• Voting: One common class carries one vote per share. Post-offering beneficial ownership includes FMR at 10.4%, Bedford Ridge at 8.9%, and directors and executives collectively at 12.2%; fund-attributed holdings are not direct personal ownership.
• Insider liquidity: Forerunner exits through the offering, while the director/executive group sells 35.6M shares, including affiliated funds—material monetization alongside continued ownership.
• Entrenchment: A three-class board, cause-only removal requiring 66⅔% approval, and restrictions on shareholder action constrain takeover and board-change opportunities.
• Conflicts: Insiders collectively own ≈11.1% of AI vendor webAI; Oura has paid $1.2M and committed another $3.5M. New equity plans initially reserve 6.0M shares and permit automatic annual increases, creating continuing dilution.

Risk Assessment

• Product quality: Warranty reserves reached $132M after $75.5M of claims; Ring 4 battery problems can impair margins, trust and repeat purchases.
• Demand and competition: Hardware supplies 80% of revenue, so premium-price competition or weaker Ring 5 demand also threatens subscription acquisition.
• Privacy and regulation: Sensitive health data and AI guidance create trust and compliance exposure; medical-device classification could delay features or restrict sales.
• Intellectual property: Samsung seeks import restrictions, while Omni MedSci seeks ≈$120M damages; adverse outcomes could disrupt availability or consume cash.
• Capital obligations: $380M debt, $120M purchase commitments and substantial repurchases constrain flexibility; the secured revolver pledges intellectual property and imposes financial covenants.
• Valuation: 14.1–15.6× FY2025 revenue requires prolonged growth and better earnings conversion, despite slowing growth and uneven quarterly profitability.
• Share supply: Early lock-up releases and equity awards can expand supply materially beyond the IPO’s 15.6% ownership stake.

Investor Actionables

The price asks buyers to accept that ring adoption becomes durable subscription earnings. Proceeds principally settle award taxes, leaving execution dependent on existing liquidity and operating cash generation.

• Membership conversion: Starting from 5.0M members and ≈85% retention, test management’s ≈5.7M FY2026 year-end expectation; sustained retention supports the case, while weaker cohorts undermine recurring economics.
• Product quality: Starting from $132M warranty reserves, track claims and provisions after Ring 5; stabilization supports margin recovery, while renewed escalation challenges product economics.
• Distribution: Starting from international hardware below 20% and two customers supplying 22% of revenue, test whether expansion diversifies growth or increases dependence on major partners.
• Earnings conversion: Starting from 74.1% revenue growth but a 5.86% operating margin, look for growth with improving profitability; persistent spending-led margin erosion weakens the valuation case.